Treatment with Mavenclad (cladribine) over two years significantly improved physical and mental health aspects of quality of life in people with highly active relapsing multiple sclerosis, according to a final analysis of data from a Phase 4 study.

Mavenclad is an oral medication approved for people with relapsing forms of MS. In clinical trials, the therapy has been shown to reduce relapses, slow disability progression, and reduce the number of brain lesions.

After its approval, a phase 4 study with 482 MS patients showed improvements in quality of life, especially limitations owing to physical problems, health distress, and emotional problems.

Here at Belong, we will continue to update you with new medical and research developments. If you are interested in participating in a clinical trial, our team will gladly assist you in finding suitable trials for your medical needs. You are invited to respond here or contact us in a new post in this group.

Best of health,
The Clinical Trial Team

For more info:
Click to visit Multiple Sclerosis News Today

This content is provided for your general education and information only. It does not necessarily reflect Belong’s views and opinions. Belong does not endorse or support any specific product, service or treatment.